Xin is a Principal in Fund III and brings ten years of pharmaceutical and management consulting experience. His role encompasses leading due diligence, structuring, negotiating, and closing deals, monitoring portfolio companies, advising on exit strategies, and quarterly and annual reporting. Xin participated in closing key deals in Fund III, including Domain Therapeutics, Amolyt Pharma, enGene, Ability Pharma, and Glycomine. He serves as a board observer for Epitopea and Ability Pharma.

Before joining CTI, Xin was a Principal of the Valuation & Financial Advisory Practice at a life sciences management consulting firm, Foster Rosenblatt (FR). In his eight-year tenure at FR, Xin worked with large pharmaceutical companies and small biotechnology start-ups on opportunity assessment, forecasting, and valuation projects to support business development deals. Xin supported Point Biopharma’s SPAC transaction, Horizon Therapeutics’ deal with Amgen, and Myocardia's deal with BMS. Xin started his career at Sanofi, where he worked as an analyst in the Manufacturing Technology department. Xin holds an MBA in finance and marketing from Schulich School of Business, York, and a Master of Biotechnology from the University of Toronto.

‍